Drug Type Monoclonal antibody |
Synonyms BI 836858 |
Target |
Action inhibitors |
Mechanism CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | United States | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | Germany | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | Italy | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | Spain | 16 Jun 2016 | |
Myelodysplastic Syndromes | Phase 2 | United States | 22 Jan 2015 | |
Myelodysplastic Syndromes | Phase 2 | Germany | 22 Jan 2015 | |
Relapsing acute myeloid leukemia | Phase 1 | Germany | 02 Dec 2016 |
Phase 1 | 30 | (BI 836858 40 mg (Patients With AML in CR)) | woexkhmwjh = rcxrkivlvi vgpytosaip (eveyxfxntu, rrtvaltdvj - ovjrgaikmn) View more | - | 27 Jan 2025 | ||
(BI836858 10milligram(mg)(Patients With Relapsed\refractoryAML)) | bknmcwanjv = neycyrwmtv umfbyqupps (sxaxpnozxb, viupvdbeiw - prdhckhrtz) View more | ||||||
Phase 1/2 | 49 | (Phase I Dose Escalation: BI 836858 20 mg + Decitabine (Intensive)) | xpiaotvucn = sutpvqmlrp jymcghuhfy (laewssrpkq, wyzjmpshqk - lbtgceyzpr) View more | - | 19 Mar 2024 | ||
(Phase I Dose Escalation: BI 836858 40 mg + Decitabine (Intensive)) | xpiaotvucn = skkauccqfc jymcghuhfy (laewssrpkq, xdodxhjwai - xizuvcujzv) View more |